SuperworthSunshine Biopharma profit margin SBFM
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- −16.5%
- Operating margin, 12 months
- −16.6%
- Net margin on a year earlier
- +0.9 pts
Over the twelve months to Jun 30, 2026, Sunshine Biopharma kept −16.5% of its revenue as net profit, with an operating margin of −16.6% and a gross margin of 30.3%.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −16.5% | −17.2% | 33.8% |
| FY2024 | −14.7% | −16.5% | 30.6% |
| FY2023 | −18.7% | −20.0% | 34.6% |
| FY2022 | n/a | n/a | 39.0% |
| FY2021 | n/a | n/a | 48.4% |
| FY2020 | n/a | n/a | 63.8% |
| FY2019 | n/a | n/a | 47.7% |
| FY2018 | n/a | n/a | −10.6% |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −16.5% | +0.9 pts | −16.6% | |
| Q1 FY26 | −17.0% | −3.1 pts | −17.8% | |
| Q4 FY25 | −16.5% | −1.7 pts | −17.2% | |
| Q3 FY25 | −16.1% | −3.2 pts | −17.3% | |
| Q2 FY25 | −17.4% | −5.3 pts | −17.9% | |
| Q1 FY25 | −13.9% | +1.4 pts | −15.8% | |
| Q4 FY24 | −14.7% | +4.0 pts | −16.5% | |
| Q3 FY24 | −12.8% | n/a | −14.9% | |
| Q2 FY24 | −12.1% | n/a | −15.0% | |
| Q1 FY24 | −15.3% | n/a | −16.2% | |
| Q4 FY23 | −18.7% | n/a | −20.0% | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.
| Company | Profit margin |
|---|---|
| SBFMSunshine Biopharma | −16.5% |
| DCOYDecoy Therapeutics | n/m |
| JAGXJaguar Health | n/m |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| NXTSNexentis Technologies | n/m |
| VBIOValion Bio | n/m |
| ARTLArtelo Biosciences | n/m |
| LNAILunai Bioworks | n/m |
| GNPXGenprex | n/m |
| GOVXGeoVax Labs | n/a |
| ONCOOnconetix | n/m |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Sunshine Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.